DNAJC22

Across TCGA pan-cancer cohorts, DNAJC22 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated DNAJC22 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DNAJC22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DNAJC22 expression acts as an unfavorable survival marker.

LUAD and HNSC are the cancer types where DNAJC22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.268	0.711	.017	12	view →
HNSC	OS	Median	All	0.151	0.685	.007	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

DNAJC22–LUAD (OS)

Open the LUAD breakdown →